Hodgkin lymphoma
HL
chemosensitive
malignancy
relapse
high-dose chemotherapy
autologous stem cell transplant
treatment
adequate
disease control
salvage chemotherapy
Regimens
inpatient administration
toxicity
Gemcitabine
cisplatin
activity
HL
toxicity
first-line
chemotherapeutics
outpatient setting
retrospective single-centre analysis
patients
relapsed
refractory
HL
treated with
gemcitabine
day
D8
D15
methylprednisolone
cisplatin
days
GEM-P
Demographic
survival
response
toxicity
data
eligible
patients
identified
age
GEM-P
administered
patients
GEM-P
second-line treatment
third-line therapy
Overall response rate
ORR
GEM-P
cohort
complete response
CR
partial response
CR
metabolic CR
PET
ORR
second-line
patients
toxicities
haematological
neutropenia
thrombocytopenia 51Â %
follow-up
GEM-P
years
GEM-P
progression-free survival
confidence interval
CI
overall survival
CI
patients
autologous transplant
GEM-P
salvage chemotherapy
transplantation
patients
treatment
relapsed
refractory
HL
